Cat. No.: HY-17359

Copy Link Print Information

Deferasirox

(Synonyms: ICL 670)

14 Cited Publications

Customer Review

Based on 14 publication(s) in Google Scholar

Deferasirox (ICL 670) is an orally available iron chelator used for the management of transfusional iron overload.

For research use only. We do not sell to patients.

Purity: 99.86%
CAS No.: 201530-41-8
Formula: C₂₁H₁₅N₃O₄
Molecular Weight:373.36

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Deferasirox Chemical Structure

CAS No.: 201530-41-8

Size

Price

Stock

Quantity

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Bulk Inquiry

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (14)
Solvent & Solubility
- In Vitro
- In Vivo
Protocol
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

Deferasirox (ICL 670) is an orally available iron chelator used for the management of transfusional iron overload^[1]^[2]^[3].

Cellular Effect

Cell Line	Type	Value	Description	References
DLD-1	IC₅₀	3.4 μM Compound: 99	Antiproliferative activity against human DLD-1 cells assessed as reduction in cell proliferation Antiproliferative activity against human DLD-1 cells assessed as reduction in cell proliferation	[PMID: 33445154]
Fibroblast	IC₅₀	100 μM Compound: Deferasirox	Cytotoxicity against human foreskin fibroblasts after 96 hrs by MTT assay Cytotoxicity against human foreskin fibroblasts after 96 hrs by MTT assay	[PMID: 20005708]
HL-60	GI₅₀	5.5 μM Compound: 27a	Antiproliferative activity against human HL-60 cells Antiproliferative activity against human HL-60 cells	[PMID: 35838529]
KYSE-150 cell line	GI₅₀	3.3 μM Compound: 27a	Antiproliferative activity against human KYSE-150 cells Antiproliferative activity against human KYSE-150 cells	[PMID: 35838529]
MDA-MB-231	IC₅₀	4 μM Compound: Deferasirox	Cytotoxicity against human MDA-MB-231 cells after 96 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 96 hrs by MTT assay	[PMID: 20005708]
MIA PaCa-2	IC₅₀	10 μM Compound: Deferasirox	Cytotoxicity against human MIAPaCa2 cells after 96 hrs by MTT assay Cytotoxicity against human MIAPaCa2 cells after 96 hrs by MTT assay	[PMID: 20005708]
NCI-H460	IC₅₀	20.36 μM Compound: DFX	Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability incubated for 48 hrs by CCK8 assay Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability incubated for 48 hrs by CCK8 assay	[PMID: 34292737]
NCI-H460	IC₅₀	98.35 μM Compound: DFX	Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability incubated for 24 hrs by CCK8 assay Cytotoxicity against human NCI-H460 cells assessed as reduction in cell viability incubated for 24 hrs by CCK8 assay	[PMID: 34292737]
SK-N-MC	IC₅₀	20.54 μM Compound: 3	Toxicity in human SK-N-MC cells by MTT method Toxicity in human SK-N-MC cells by MTT method	[PMID: 20041672]
SW480	IC₅₀	3.9 μM Compound: 99	Antiproliferative activity against human SW480 cells assessed as reduction in cell proliferation Antiproliferative activity against human SW480 cells assessed as reduction in cell proliferation	[PMID: 33445154]

In Vitro

In LX-2 cells treated with 50 μM deferasirox for 12 h, α1(I)procollagen expression is decreased by 25%, with maximal reductions (10-fold) seen following 24-120 h of treatment. Similarly, α-smooth muscle actin (αSMA) expression is significantly lower^[1]. Deferasirox had anti-proliferative effects on HL-60 or KG-1 myeloid leukemia cell lines at a concentration as low as 5 μM . The cytotoxicity is both dose and time dependent^[2]. The viability of both EL4 cells and L1210 cells incubated with deferasirox decrease in a concentration-dependent manner^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

The tumor is significantly smaller in the SIO mice treated with deferasirox compared with control. Mice treated with DFX showed longer survival than the other groups. Deferasirox has a survival benefit for SIO leukemia murine model in terms of iron chelation and antileukemic therapy^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 201530-41-8
Appearance Solid
Molecular Weight 373.36
Formula C₂₁H₁₅N₃O₄
Color White to light brown
SMILES

O=C(O)C1=CC=C(N2N=C(C3=CC=CC=C3O)N=C2C4=CC=CC=C4O)C=C1
Synonyms

ICL 670
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (14)

All Bio/Physico-chemical AssayWBMicrobiological AssayCell Imaging/Staining

Sort by:

Journal Impact Factor

J Clin Invest

Iron supplementation alleviates pathologies in a mouse model of facioscapulohumeral muscular dystrophy. [Abstract]

2025 Jul 1;135(17):e181881. PMID: 40591405
Phytomedicine

Shikonin induces ferroptosis in osteosarcomas through the mitochondrial ROS-regulated HIF-1α/HO-1 axis. [Abstract]

2024 Dec:135:156139. PMID: 39423479
Oncogene

Discovery of ferroptosis-inducing R4VP compounds for targeting aggressive cancers. [Abstract]

2026 Jul;45(27):2727-2742. PMID: 42243330
Cell Rep

TCF25 serves as a nutrient sensor to orchestrate metabolic adaptation and cell death by enhancing lysosomal acidification under glucose starvation. [Abstract]

2025 Aug 21;44(9):116186. PMID: 40844875
Antioxidants (Basel)

Deferasirox Causes Leukaemia Cell Death through Nrf2-Induced Ferroptosis. [Abstract]

2024 Mar 29;13(4):424. PMID: 38671872

Deferasirox purchased from MedChemExpress. Usage Cited in: Antioxidants (Basel). 2024 Mar 29;13(4):424. [Abstract]

Western blotting was conducted to assess the levels of autophagic markers (LC3B, ATG5, ATG12, and ATG16L1) in lysates of Sup-B15 and Molt-4 cells after Deferasirox (100 nM, 24 h) treatment.

Deferasirox purchased from MedChemExpress. Usage Cited in: Antioxidants (Basel). 2024 Mar 29;13(4):424. [Abstract]

Intracellular ROS levels were measured as fold increases in fluorescence relative to the negative control after 0, 1, 2, 4, and 8 h exposures of Sup-B15 cells to Deferasirox (100 nM) treatment.
Antioxidants

Syk Kinase Inhibitors Synergize with Artemisinins by Enhancing Oxidative Stress in Plasmodium falciparum-Parasitized Erythrocytes. [Abstract]

2020 Aug 14;9(8):753. PMID: 32824055

Deferasirox purchased from MedChemExpress. Usage Cited in: Antioxidants. 2020 Aug 14;9(8):753. [Abstract]

Intensity of EPR spectra (arbitrary units) in the presence of PBN spin trapping agent in pRBCs treated with/without P505-15 (0.5 μΜ) for 24 h with/without 10-min incubation with DHA (200 µΜ) and with different concentrations (100–400 µM) of Deferasirox (DFX).

Deferasirox purchased from MedChemExpress. Usage Cited in: Antioxidants. 2020 Aug 14;9(8):753. [Abstract]

Isobolograms showing the interactions between Syk Inhibitors (P505-15 and R406) and dihydroartemisinin (DHA) and artesunate (AS) in combination with the iron chelator Deferasirox (DFX), after 24 h of incubation in the P. falciparum Palo Alto strain. Synchronized P. falciparum cultures were treated for 24 h with different concentrations (from 0.05 to 2.5 µM) of representative Syk inhibitors (P505-15 and R406) in combination with different concentrations of DHA and AS (from 0.6 to 10 nM) using a fixed concentration (50 µM) of the iron chelator Deferasirox (DFX) at the ring stage.
Environ Health

2025 Nov 28，XXXX(XXX).
Cells

The Thrombopoietin Receptor Agonist Eltrombopag Inhibits Human Cytomegalovirus Replication Via Iron Chelation. [Abstract]

2019 Dec 20;9(1):31. PMID: 31861948
FASEB J

Penicillide Triggers Immunogenic Pyroptosis in Tumor Cells via Oxidative Stress/NF-κB/GSDMD Signaling Axis. [Abstract]

2026 Mar 31;40(6):e71636. PMID: 41842655
Bioengineered

Platycodin D regulates high glucose-induced ferroptosis of HK-2 cells through glutathione peroxidase 4 (GPX4). [Abstract]

2022 Mar;13(3):6627-6637. PMID: 35226829

Deferasirox purchased from MedChemExpress. Usage Cited in: Bioengineered. 2022 Mar;13(3):6627-6637. [Abstract]

HK-2 cells were incubated in NG or HG conditions, and both were treated with DFX and erastin. Deferasirox (200 μM) treatment markedly suppressed LDH activity.
PLoS Negl Trop Dis

Identification of anti-flaviviral drugs with mosquitocidal and anti-Zika virus activity in Aedes aegypti. [Abstract]

2019 Aug 20;13(8):e0007681. PMID: 31430351
Metallomics

ATH434, a promising iron-targeting compound for treating iron regulation disorders. [Abstract]

2024 Oct 4;16(10):mfae044. PMID: 39317669

Deferasirox purchased from MedChemExpress. Usage Cited in: Metallomics. 2024 Oct 4;16(10):mfae044. [Abstract]

Anaerobic Fe²⁺ competition binding assay for DFX, DFP, DMOG, and IOX3. Representative titration absorption spectra with corresponding binding profiles of Mag-Fura-2 competing for Fe²⁺ ions with Deferasirox.
Gene

Functional indications for transposase domestications - Characterization of the human piggyBac transposase derived (PGBD) activities. [Abstract]

2022 Aug 5:834:146609. PMID: 35609796
Wayne State University

2025.

Solvent & Solubility

In Vitro:

DMSO : ≥ 100 mg/mL (267.84 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.6784 mL

13.3919 mL

26.7838 mL

5 mM

0.5357 mL

2.6784 mL

5.3568 mL

10 mM

0.2678 mL

1.3392 mL

2.6784 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (6.70 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (6.70 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (6.70 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocol

Cell Assay^[2]

Deferasirox is dissolved in DMSO. HL-60 or KG-1 cells are treated with 0, 5, 10, 50 μM of deferasirox for 24 or 48 h, and proliferation is determined by an MTT assay^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[3]

Mice: Murine leukemia cells are injected subcutaneously into the right flank of mice. Deferasirox is dissolved in distilled water and orally administered at 20 mg/kg until the cumulative dose reaches 300 mg/kg. The mice are observed and weighed daily^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (284 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Sobbe A, et al. Inconsistent hepatic antifibrotic effects with the iron chelator deferasirox. J Gastroenterol Hepatol. 2015 Mar;30(3):638-45. [Content Brief]

[2]. Kim JL, et al. The oral iron chelator deferasirox induces apoptosis in myeloid leukemia cells by targetingcaspase. Acta Haematol. 2011;126(4):241-5. [Content Brief]

[3]. Lee DH, et al. Deferasirox shows in vitro and in vivo antileukemic effects on murine leukemic cell lines regardless of iron status. Exp Hematol. 2013 Jun;41(6):539-46. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.6784 mL	13.3919 mL	26.7838 mL	66.9595 mL
	5 mM	0.5357 mL	2.6784 mL	5.3568 mL	13.3919 mL
	10 mM	0.2678 mL	1.3392 mL	2.6784 mL	6.6960 mL
	15 mM	0.1786 mL	0.8928 mL	1.7856 mL	4.4640 mL
	20 mM	0.1339 mL	0.6696 mL	1.3392 mL	3.3480 mL
	25 mM	0.1071 mL	0.5357 mL	1.0714 mL	2.6784 mL
	30 mM	0.0893 mL	0.4464 mL	0.8928 mL	2.2320 mL
	40 mM	0.0670 mL	0.3348 mL	0.6696 mL	1.6740 mL
	50 mM	0.0536 mL	0.2678 mL	0.5357 mL	1.3392 mL
	60 mM	0.0446 mL	0.2232 mL	0.4464 mL	1.1160 mL
	80 mM	0.0335 mL	0.1674 mL	0.3348 mL	0.8370 mL
	100 mM	0.0268 mL	0.1339 mL	0.2678 mL	0.6696 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Deferasirox

Anti-Infection Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Drug Repurposing Compound Library

Oxygen Sensing Compound Library

Antibacterial Compound Library

Ferroptosis Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Drug-Induced Liver Injury (DILI) Compound Library

Anti-Blood Cancer Compound Library

Rare Diseases Drug Library

Pediatric Drug Library

EMA-Approved Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Non-steroidal Anti-Inflammatory Compound Library

Off-patent Drug Library

Cell Death Library

Anti-Hematopathy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Publications Citing Use of MedChemExpress (MCE) Deferasirox

Biological Activity

Chemical Information

Publications (14)

Solvent & Solubility

Protocol

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Deferasirox Related Classifications

Cat. No.: HY-17359